AR065796A1 - Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina - Google Patents

Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina

Info

Publication number
AR065796A1
AR065796A1 ARP080101144A ARP080101144A AR065796A1 AR 065796 A1 AR065796 A1 AR 065796A1 AR P080101144 A ARP080101144 A AR P080101144A AR P080101144 A ARP080101144 A AR P080101144A AR 065796 A1 AR065796 A1 AR 065796A1
Authority
AR
Argentina
Prior art keywords
disorder
depression
addition salt
salt
acid
Prior art date
Application number
ARP080101144A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR065796A1 publication Critical patent/AR065796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1: Una formulacion farmacéutica líquida que comprende una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion de ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion del ácidoL-aspártico y la sal de adicion del ácido glutámico. Reivindicacion 15: Una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion del ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion delácido L-aspártico y la sal de adicion del ácido glutámico para utilizar en el tratamiento de una enfermedad seleccionada entre trastornos del estado de ánimo, trastorno depresivo mayor, trastorno de ansiedad generalizada, depresion atípica,depresion bipolar, trastorno de ansiedad social, trastorno obsesivo compulsivo, trastorno de pánico, trastorno de estrés post-traumático, abuso, trastorno alimenticio, trastorno del sueno, enfermedad de Alzheimer, demencia, dolor cronico, depresionasociada con deterioro cognitivo, depresion asociada con psicosis, deterioro cognitivo en la esquizofrenia, depresion o ansiedad asociada con dolor, alteraciones del comportamiento en las personas mayores de edad, ADHD, melancolía, depresionresistente al tratamiento o depresion con síntomas residuales, donde dicha sal está en una formulacion farmacéutica líquida.
ARP080101144A 2007-03-20 2008-03-19 Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina AR065796A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
DKPA200701790 2007-12-14

Publications (1)

Publication Number Publication Date
AR065796A1 true AR065796A1 (es) 2009-07-01

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101144A AR065796A1 (es) 2007-03-20 2008-03-19 Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina

Country Status (27)

Country Link
US (1) US20100105730A1 (es)
EP (2) EP2129377B1 (es)
JP (1) JP5301474B2 (es)
KR (1) KR20090130000A (es)
AR (1) AR065796A1 (es)
AT (1) ATE526966T1 (es)
AU (1) AU2008228637B2 (es)
BR (1) BRPI0808820A2 (es)
CA (1) CA2684592C (es)
CL (1) CL2008000797A1 (es)
CO (1) CO6220958A2 (es)
CY (1) CY1112285T1 (es)
DK (1) DK2129377T3 (es)
EA (1) EA019695B1 (es)
ES (1) ES2373275T3 (es)
HK (1) HK1140949A1 (es)
HR (1) HRP20110844T1 (es)
IL (1) IL200959A (es)
MX (1) MX2009009388A (es)
MY (1) MY148695A (es)
NZ (1) NZ579717A (es)
PL (1) PL2129377T3 (es)
PT (1) PT2129377E (es)
RS (1) RS52050B (es)
SI (1) SI2129377T1 (es)
TW (1) TWI405588B (es)
WO (1) WO2008113358A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
SI2167085T1 (sl) * 2007-06-15 2014-05-30 H. Lundbeck A/S 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
US8940746B2 (en) 2009-04-24 2015-01-27 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
WO2011136373A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
US20130115292A1 (en) 2010-04-30 2013-05-09 Takeda Pharmaceutical Company Limited Enteric tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1446328B1 (en) 2001-10-16 2017-05-31 Medical Instill Technologies, Inc. DISPENSER WITH SEALED CHAMBER AND ONE−WAY VALVE FOR PROVIDING METERED AMOUNTS OF SUBSTANCES
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
MXPA05009592A (es) * 2003-04-04 2005-10-18 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina.
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
JP2010521500A (ja) 2010-06-24
IL200959A0 (en) 2010-05-17
EA019695B1 (ru) 2014-05-30
EA200970869A1 (ru) 2010-02-26
SI2129377T1 (sl) 2012-01-31
DK2129377T3 (da) 2012-01-02
TW200902083A (en) 2009-01-16
EP2129377B1 (en) 2011-10-05
IL200959A (en) 2011-12-29
EP2388004A1 (en) 2011-11-23
BRPI0808820A2 (pt) 2014-08-19
EP2129377A1 (en) 2009-12-09
ES2373275T3 (es) 2012-02-01
HK1140949A1 (en) 2010-10-29
ATE526966T1 (de) 2011-10-15
CO6220958A2 (es) 2010-11-19
US20100105730A1 (en) 2010-04-29
MX2009009388A (es) 2009-11-25
HRP20110844T1 (hr) 2011-12-31
JP5301474B2 (ja) 2013-09-25
CA2684592A1 (en) 2008-09-25
WO2008113358A1 (en) 2008-09-25
PL2129377T3 (pl) 2012-02-29
MY148695A (en) 2013-05-31
CY1112285T1 (el) 2015-12-09
CA2684592C (en) 2013-11-12
TWI405588B (zh) 2013-08-21
AU2008228637A1 (en) 2008-09-25
KR20090130000A (ko) 2009-12-17
PT2129377E (pt) 2011-12-23
CL2008000797A1 (es) 2008-09-26
RS52050B (en) 2012-04-30
NZ579717A (en) 2012-06-29
AU2008228637B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
AR076400A1 (es) Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente
AR065796A1 (es) Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina
Daneshpazhooh et al. Mucocutaneous findings in 100 children with Down syndrome
Carlson et al. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation
López‐Jornet et al. A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
Park et al. The analysis of risk factors influencing adolescent suicidal ideation in a multicultural family-based on the 2012 Korean youth health risk behavior on-line survey
AR098599A2 (es) Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
Baruch et al. Treatment for depression comorbid with dementia
Granata Comprehensive care of children with Dravet syndrome
Earle An introduction to the psychopharmacology of children and adolescents with autism spectrum disorder
Kowal et al. Bilastine as a potential treatment in allergic rhinitis
Stringaris The new DSM is coming-it needs tough love...
CA2614731A1 (en) Multimediator dopamine transport inhibitors, and uses related thereto
Paris Personality disorders and mood disorders: Phenomenological resemblances vs. pathogenetic pathways
Bohlmeijer et al. Positive clinical interventions: Why are they important and how do they work?
Sogolitappeh et al. Effectiveness of group life skills training on decreasing anxiety and depression among heart patients, after bypass surgery
Rappa et al. Condensed psychopharmacology 2013: a pocket reference for psychiatry and psychotropic medications
Pontoski et al. Psychotherapy for social anxiety disorder.
Cordero Jr I will survive!: saving the extroverts through virtual interaction during the COVID-19 pandemic
Lan et al. Nursing Experience of Using Mirror Visual Feedback for a Schizophrenia Patient With Visual Hallucinations
BRPI0405989A (pt) artigo plastificado para tratamento da pele
Milev Book Review: Mood Disorders: Advances in Treatment of Bipolar Disorder

Legal Events

Date Code Title Description
FB Suspension of granting procedure